Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

被引：0
|
作者：
Pia Wegman
Sauli Elingarami
John Carstensen
Olle Stål
Bo Nordenskjöld
Sten Wingren
机构：
[1] Linköping University,Department of Biomedicine and Surgery, Division of Cell Biology, Faculty of Health Sciences
[2] Linköping University,Department of Health and Society, Faculty of Arts and Sciences
[3] Linköping University,Department of Biomedicine and Surgery, Division of Oncology, Faculty of Health Sciences
来源：
Breast Cancer Research | / 9卷
关键词：
Breast Cancer; Tamoxifen; Postmenopausal Patient; Tamoxifen Therapy; Homozygous Carrier;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
    Chan, Carmen W. H.
    Law, Bernard M. H.
    So, Winnie K. W.
    Chow, Ka Ming
    Waye, Mary M. Y.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1395 - 1404
  • [32] CYP2D6 tamoxifen: Pharmacogenetics in early breast cancer
    Brauch H.
    Schroth W.
    Der Gynäkologe, 2010, 43 (7): : 579 - 585
  • [33] Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer
    Boucenna, Amira
    Boudaoud, Khadidja
    Hireche, Ahmed
    Rezgoune, Mohamed Larbi
    Abadi, Noureddine
    Filali, Taha
    Satta, Dalila
    EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2022, 23 (01)
  • [34] Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer
    Amira Boucenna
    Khadidja Boudaoud
    Ahmed Hireche
    Mohamed Larbi Rezgoune
    Noureddine Abadi
    Taha Filali
    Dalila Satta
    Egyptian Journal of Medical Human Genetics, 23
  • [35] Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 Are Associated with Early Age Acute Leukemia
    Lopes, Bruno Almeida
    Emerenciano, Mariana
    Aguiar Goncalves, Bruno Alves
    Vieira, Tallita Meciany
    Rossini, Ana
    Pombo-de-Oliveira, Maria S.
    PLOS ONE, 2015, 10 (05):
  • [36] Impact of CYP2D6 inhibitors on tamoxifen metabolism in breast cancer patients
    Keller, Denise
    Medwid, Samantha
    Schwarz, Ute
    Legan, Robin
    Kim, Richard
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 250 - 253
  • [37] Tamoxifen Resistance and CYP2D6 Copy Numbers in Breast Cancer Patients
    Motamedi, Sahar
    Majidzadeh, Keivan
    Mazaheri, Mahta
    Anbiaie, Robab
    Mortazavizadeh, Seyed Mohammad Reza
    Esmaeili, Rezvan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (12) : 6101 - 6104
  • [38] CYP2D6 genotype and tamoxifen response in pre and postmenopausal Thai women with hormone responsive breast cancer
    Noonpakdee, W.
    Chamnanphon, M.
    Sukasem, C.
    Chantratita, W.
    Pasomsub, E.
    FEBS JOURNAL, 2013, 280 : 311 - 312
  • [39] SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen
    Moyer, Ann M.
    Suman, Vera J.
    Weinshilboum, Richard M.
    Avula, Rajeswari
    Black, John L.
    Safgren, Stephanie L.
    Kuffel, Mary J.
    Ames, Matthew M.
    Ingle, James N.
    Goetz, Matthew P.
    PHARMACOGENOMICS, 2011, 12 (11) : 1535 - 1543
  • [40] Correlations between Genetic Variants in CYP2D6 and UGT2B7 and Survival in Breast Cancer Patients Treated with or without Tamoxifen: Results from a Large Cohort Study
    Oesterreich, S.
    Hilsenbeck, S. H.
    Skaar, T.
    Hartmaier, R. J.
    Flockhart, D. A.
    Sikora, M. J.
    Osborne, C. K.
    Rae, J. M.
    CANCER RESEARCH, 2010, 70
12345